论文部分内容阅读
目的评价特异性免疫治疗对过敏性紫癜(Henoch-Schonlein purpura,HSP)患者的临床意义。方法将门诊及住院的HSP患者随机分为治疗组和对照组各30例,治疗组采用特异性免疫治疗,治疗过程分为常规脱敏和维持脱敏两个阶段。观察HSP发作时间;HSP发作次数、就诊次数、住院次数、住院天数。时间为78周。对照组不作脱敏治疗。结果HSP症状体征存在的天数治疗组比对照组明显减少(t=3.295,P<0.01)疗程结束后患者HSP症状改善情况自我评价治疗组优于对照组(u=3.284,P<0.01)。患者HSP发作次数、就诊次数、住院次数、住院天数均明显降低。治疗过程中均未出现明显不良反应。结论特异性免疫疗法,能减轻HSP症状,减少发作、就诊、住院次数及住院天数,并具有一定的安全性。
Objective To evaluate the clinical significance of specific immunotherapy in patients with Henoch-Schonlein purpura (HSP). Methods Outpatients and inpatients with HSP were randomly divided into treatment group and control group of 30 cases, the treatment group using specific immunotherapy, the treatment process is divided into two stages of conventional desensitization and maintenance of desensitization. The onset time of HSP was observed; the number of HSP seizures, the number of visits, the number of hospitalizations and the days of hospitalization. The time is 78 weeks. The control group did not make desensitization treatment. Results The number of days in which symptoms and signs of HSP were present was significantly lower in the treatment group than in the control group (t = 3.295, P <0.01). The improvement of HSP in the treatment group was better than that in the control group (u = 3.284, P <0.01). The number of patients with HSP attack, the number of visits, hospitalization, hospitalization days were significantly lower. No significant adverse reactions occurred during the course of treatment. Conclusion Specific immunotherapy can relieve the symptoms of HSP and reduce the number of attacks, visits, hospitalizations and days of hospitalization, and has some safety.